Clinical Trials

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

The PAS 2026 meeting is more than a conference; it's a convergence of science, capital, and community, signaling major shifts in pediatric care.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.